App-Quantinova.ai

Visualzing toxicity: A single score to summarize toxicity in randomized clinical trials.

Mariana Carbini - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pre-treatment evaluation of LVEF for breast cancer patients receiving anthracyclines: Is it necessary?

Prakash Peddi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The impact of body weight status on health care utilization and costs among long-term cancer survivors.

Xuesong Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Financial toxicity in children, adolescent, and young adult cancer patients and their families: A large national registry analysis from the family reach foundation.

Lori S. Muffly - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Potential cost savings by dose rounding monoclonal antibodies (mAB) in a community cancer center.

Mehmet Sitki Copur - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Obinutuzumab

The burden and direct cost of cancer in Europe (EU-28).

Nils Erik Wilking - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Is there a link between value as defined by ESMO-MCBS and uptake of new drugs?

Peter Lindgren - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Financial toxicity in adults with cancer: Adverse outcomes and potential areas of intervention.

Thomas Gregory Knight - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Rising financial burden of targeted oral anticancer medications on the Medicare Part D program and its beneficiaries.

Ya-Chen T. Shih - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Modeling the cost of immune checkpoint inhibitor-related toxicities.

Neil Thomas Mason - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

What role should value play in cancer care?

Risha Gidwani - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient-reported outcomes (PRO) from a global phase 3 randomized controlled trial (RCT) of inotuzumab ozogamicin (InO) vs standard care (SC) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Hagop M Kantarjian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Inotuzumab ozogamicin

Uptake of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists treating adolescent and young adults (AYA): A population based analysis across Northern California.

Parveen Shiraz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients.

Ahmad Alhuraiji - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Jun Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).

Andrew M. Evens - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bendamustine

Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.

David W. Scott - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.

Michael Crump - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of IgVH mutational status in patients with chronic lymphocytic leukemia with isolated good and intermidiate risk genetic aberrations.

Jose David Sandoval-Sus - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Treatment trends and outcomes in early-stage Hodgkin lymphoma in elderly: A National Cancer Data Base analysis.

Gaurav Goyal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts